Noradrenergic function in generalized anxiety disorder: Effects of yohimbine in healthy subjects and patients with generalized anxiety disorder
References (35)
- et al.
Naltrexone precipitated opiate withdrawal in methadone addicted human subjects: Evidence for noradrenergic hyperactivity
Life Sciences
(1984) - et al.
Severe anxiety produced by FG7142, a β-carboline ligand for benzodiazepine receptors
Lancet
(1983) - et al.
Elevations of urinary MHPG in depressed patients with panic attacks
Psychiatry Research
(1987) Single unit activity of locus coeruleus neurons in behaving animals
Progress in Neurobiology
(1986)Peripheral catecholamine administration does not alter cerebral β-adrenergic receptor density
Brain Research
(1983)Regatine and benadine in the diagnoses of pheochromocytoma
Medical Clinics of North America
(1954)DSM-III: Diagnostic and Statistical Manual of Mental Disorders
(1980)- et al.
Benzodiazepine receptors
The psychophysiology of anxiety: With a review of literature concerning adrenaline
Journal of Nervous and Mental Disease
(1964)- et al.
The diagnostic validity of anxiety disorders and their relationship to depressive illness
American Journal of Psychiatry
(1985)
Urinary MHPG, stress response, personality factors and somatosensory evoked potentials in normal subjects and patients with major affective disorders
Neuropsychobiology
(1981)
Platelet α2-adrenergic receptor binding and plasma catecholamines: Before and during imipramine treatment in patients with panic anxiety
Archives of General Psychiatry
(1984)
Abnormal regulation of noradrenergic function in panic disorders: Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder
Archives of General Psychiatry
(1986)
Noradrenergic function in panic anxiety: Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder
Archives of General Psychiatry
(1984)
Assessment of alpha-2 adrenergic autoreceptor function in humans: Effects of oral yohimbine
Life Sciences
(1984)
Abrupt discontinuation of tricyclic antidepressant drugs: Evidence of noradrenergic hyperactivity
British Journal of Psychiatry
(1982)
Neurobiological mechanisms of panic anxiety: Biochemical and behavioral correlates of yohimbine-induced panic attacks
American Journal of Psychiatry
(1987)
Cited by (84)
Yohimbine enhancement of exposure therapy for social anxiety disorder: A randomized controlled trial
2014, Biological PsychiatryCitation Excerpt :Our study also replicates both published studies of yohimbine augmentation of exposure therapy in finding that low doses of yohimbine HCl (ten 10.8 mg in these studies) are not associated with adverse events (20,21). These findings are inconsistent with studies documenting increased nervousness among healthy control subjects after administration of intravenous yohimbine (47) or 20 mg of oral yohimbine (48) but consistent with other reports on the safety of acute and chronic administration of lower doses of oral yohimbine in healthy individuals (11). In terms of mechanism of action, our study was designed to minimize the influence of enhanced autonomic symptoms and anxiety on exposure outcome.
Cannabinoid receptor signaling and modulation of monoamines: Implications for psychiatric and neurological disorders
2012, Progress in Neuro-Psychopharmacology and Biological PsychiatryGeneralized anxiety disorder
2012, Handbook of Clinical NeurologyFear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs
2010, Pharmacology Biochemistry and Behavior
Copyright © 1989 Published by Elsevier Ltd.